

# Scientific research has discovered that physiological responses to weight loss trigger weight regain

Weight loss in people with obesity has been shown to cause a change in the levels of their appetite hormones—increasing hunger and the desire to eat for at least 1 year<sup>21</sup>

Multiple hormones, such as ghrelin, GLP-1, and leptin, play an important role in regulating appetite.<sup>5</sup>

The brain plays a central role in regulating appetite and energy balance.<sup>5</sup> Metabolic adaptations that occur in response to weight loss include:<sup>21–24</sup>



Obesity is not caused by a lack of willpower or motivation. Physiological factors, including changes in the appetite hormones that favour weight regain, may be one of the challenges people living with obesity or overweight face after weight loss.<sup>15,21</sup>

Adapted from Sumithran P, et al. (2011); Schwartz A, et al. (2010); Sumithran P, et al. (2013).



GLP-1, glucagon-like peptide-1.

# Canadian guidelines for obesity management<sup>15</sup>

## What is the current approach to obesity management?

For your patients, an approach for the long-term management of obesity may involve a combination of treatments:

- Behavioural modifications
  - Nutrition
  - Physical activity
  - Cognitive-behaviour therapy
- Pharmacotherapy (in combination with lifestyle modifications)
  - For patients with BMI  $\geq 27$  kg/m<sup>2</sup> with risk factors or BMI  $\geq 30$  kg/m<sup>2</sup>
  - Consider if the patient has not lost 0.5 kg (1lb) per week by 3–6 months after lifestyle changes
- Bariatric surgery (in combination with lifestyle modifications)
  - BMI  $\geq 35$  kg/m<sup>2</sup> with risk factors or BMI  $\geq 40$  kg/m<sup>2</sup>
  - Consider if other weight loss attempts have failed (requires lifelong medical monitoring)



**References:** 1. Canadian Medical Association. CMA recognizes obesity as a disease. 2015. Available at: <https://www.cma.ca/En/Pages/cma-recognizes-obesity-as-a-disease.aspx>. Retrieved November, 2018. 2. Obesity Canada. 5As of obesity management. 2017. Available at: <https://obesitycanada.ca/resources/5as/>. Retrieved March, 2019. 3. Mechanick J, et al. American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. *Endocrine Practice*. 2012. 4. Obesity Education Initiative, et al. *Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report*. Bethesda, MD: National Institutes of Health; 1998. 5. Badman MK, et al. The gut and energy balance: Visceral allies in the obesity wars. *Science*. 2005;307(5717):1909-1914. 6. Twells LK, et al. Current and predicted prevalence of obesity in Canada: A trend analysis. *CMAJ Open*. 2014;2(1):E18-E26. 7. Statistics Canada. Table 117-0005 - Distribution of the household population by adult body mass index (BMI) - Health Canada (HC) classification, by sex and age group, occasional (number), CANSIM (database). Retrieved November 2018. 8. Obesity Canada. Edmonton Obesity Staging System. Available at: <https://obesitycanada.ca/understanding-obesity/how-is-obesity-measured/>. Retrieved March 17, 2020. 9. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: Collaborative analyses of 57 prospective studies. *Lancet*. 2009;373(9669):1083-1096. 10. Janssen I. The public health burden of obesity in Canada. *Can J Diabetes*. 2013;37(2):90-96. 11. Grover SA, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: A modelling study. *Lancet Diabetes Endocrinol*. 2015;3(2):114-122. 12. Must A, et al. The disease burden associated with overweight and obesity. *JAMA*. 1999;282(16):1523-1529. 13. Freedhoff Y, et al. Best weight: A practical guide to office-based obesity management. *Obesity Canada*. 2010. 14. Li C, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005–2006. *Prev Med*. 2010;51(1):18-23. 15. Lau DCW, et al. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children. *CMAJ*. 2007;176(8):1-117. 16. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;2002(346):393-403. 17. World Health Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. *World Health Organ Tech Rep Ser*. 2000;894:1-253. 18. Wing RR, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes Care*. 2011;34(7):1481-1486. 19. Peppard PE, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*. 2000;284(23):3015-3021. 20. Warkentin L, et al. The effect of weight loss on health-related quality of life: Systematic review and meta-analysis of randomized trials. *Obes Rev*. 2014;15(3):169-182. 21. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. *New England Journal of Medicine*. 2011;365(17):1597-1604. 22. Schwartz A, et al. Relative changes in resting energy expenditure during weight loss: A systematic review. *Obesity Reviews*. 2010;11(7):531-547. 23. Sumithran P, et al. The defence of body weight: A physiological basis for weight regain after weight loss. *Clinical Science*. 2013;124(4):231-241. 24. Rosenbaum M, et al. Energy intake in weight-reduced humans. *Brain Research*. 2010;1350:95-102.

All trademarks are owned by Novo Nordisk A/S and used by Novo Nordisk Canada Inc. **Novo Nordisk Canada Inc.**, Tel: (905) 629-4222 or 1-800-465-4334. [www.novonordisk.ca](http://www.novonordisk.ca) © Novo Nordisk Canada Inc. CA200B00001E



# Obesity is a chronic disease that requires long-term management

“It is important for healthcare providers to recognize obesity as a disease so preventive measures can be put in place and patients can receive the appropriate treatment.”<sup>1</sup>

—CMA (Canadian Medical Association)

“Obesity is a chronic and often progressive condition not unlike diabetes or hypertension.”<sup>2</sup>

—Obesity Canada

“[Obesity] must be viewed as a chronic disorder that essentially requires perpetual care, support, and follow-up.”<sup>3</sup>

—AAACE (American Association of Clinical Endocrinologists)

Obesity is a complex, chronic medical condition that is influenced by multiple factors including:<sup>4,5</sup>


- Genetics
- Physiological responses
- Environment
- Behaviour

## Obesity is highly prevalent in Canada

- **3-fold** increase in self-reported prevalence from 1985<sup>6</sup>
- **1 in 4** Canadian adults were obese as of 2013<sup>7</sup>
- **1 in 9** Canadian adults had class II or III obesity (BMI  $\geq 35$  kg/m<sup>2</sup>) as of 2013<sup>7</sup>

## How do we classify obesity?

Obesity Class (I–III) is based on BMI and is a measure of height relative to weight.<sup>2</sup>



**Obesity Stage (Edmonton Obesity Staging System, EOSS) is based on the medical, mental, and functional impact of obesity and is a measure of how healthy the person is.<sup>2</sup>**



Adapted from Obesity Canada.

BMI is a measure of a person's size. To determine a person's overall health, the EOSS helps clinicians grade obesity based on simple criteria obtained from a patient's medical history, physical examination, and standard diagnostic tests.<sup>8</sup>

## The weight of obesity on Canadians

Obesity is a complex, multifactorial disease with a substantial personal impact

- Life expectancy decreases with increasing BMI  
Compared to a person living with overweight, class I obesity is associated with:<sup>9</sup>
- 60–120% increased diabetic, renal, and hepatic mortality
  - 40% increased vascular mortality
  - 20% increased respiratory mortality

An estimated **10,648 premature deaths** occurred in Canada in 2011 as a direct consequence of obesity.<sup>10</sup>

Compared to a woman aged 20–39 with a normal BMI (18.5–24.9 kg/m<sup>2</sup>), a woman's predicted lifespan is:<sup>11</sup>

- 5.6 years less** with class I obesity (BMI of 30–35 kg/m<sup>2</sup>)
- 6.1 years less** with class II–III obesity (BMI ≥ 35 kg/m<sup>2</sup>)

Compared to a man aged 20–39 with a normal BMI (18.5–24.9 kg/m<sup>2</sup>), a man's predicted lifespan is:<sup>11</sup>

- 5.9 years less** with class I obesity (BMI of 30–35 kg/m<sup>2</sup>)
- 8.4 years less** with class II–III obesity (BMI ≥ 35 kg/m<sup>2</sup>)

Adapted from Grover SA, et al. Estimation of the years of life lost for people with class I, II, or III obesity compared to people with a normal BMI (18.5–25 kg/m<sup>2</sup>) based on a disease-simulation model. Data are based on cardiometabolic risk factors in US adults in the National Health Examinations and Nutrition Survey data from 2003–2010.



Studies have shown various health consequences of class II obesity:<sup>12–14</sup>

- A** **5–8 times** greater prevalence of type 2 diabetes<sup>12</sup>
- B** **2-fold** greater prevalence of hypertension<sup>12</sup>
- C** **2–3 times** greater prevalence of coronary heart disease<sup>12</sup>
- D** **1.3 times** greater prevalence of dyslipidemia<sup>12</sup>
- E** **5-fold** greater risk of major depression<sup>13</sup>
- F** **> 17 times** greater prevalence of sleep apnea<sup>14</sup>
- G** **2–3 times** greater prevalence of osteoarthritis<sup>12</sup>

Multiple chronic diseases are associated with obesity.<sup>15</sup>

Obesity and its complications have a significant burden on people with obesity and can affect their families and their caregivers.

## Substantial benefits have been associated with weight loss

“The first goal is to **STABILIZE** weight and **PREVENT** further weight gain. Substantial health benefits have been seen with **MODEST** (5–10%) weight loss.”<sup>2</sup>  
—Obesity Canada

## Weight loss in people living with obesity



\* Weight lost from start.  
† Diabetes, cardiovascular.  
Example for illustrative purposes only.

## The potential health benefits of 5–10% weight loss include:

- **58% reduction in the risk of developing type 2 diabetes<sup>16</sup>**
- **Improved glycemic control<sup>17</sup>**
  - 0.5% reduction in A1C<sup>18</sup>
  - 1.1 mmol/L reduction in fasting blood glucose<sup>18</sup>
- **Reduced blood pressure<sup>17</sup>**
- **Reduced cholesterol levels<sup>17</sup>**
- **30% decrease in sleep apnea symptoms<sup>19</sup>**
  - Reduced frequency of sleep apnea, improved sleep quality, and reduced daytime somnolence<sup>17</sup>
- **Improved health-related quality of life (HRQoL) in people living with obesity, particularly physical aspects<sup>20</sup>**
- **Alleviated osteoarthritis, and back and joint pain<sup>17</sup>**
- **Improved lung function and breathlessness<sup>17</sup>**

QoL, quality of life.